Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

10
New Strong Sell Stocks for August 8th

2018-08-08 zacks
Alphatec Holdings, Inc. (ATEC - Free Report) is the designer and developer of products for the surgical treatment of spine disorders. The Zacks Consensus Estimate for its current year earnings has been revised 10% downward over the last 30 days.
VREX ELY BLKB ATEC IPGP CUI RYB ICBK

6
Alphatec Holdings, Inc. (ATEC) CEO Patrick Miles on Q2 2018 Results - Earnings Call Transcript

2018-08-05 seekingalpha
Good afternoon, everyone, and welcome to Alphatec Second Quarter 2018 Conference Call. We would like to remind everyone that participants on the call will make forward-looking statements. These statements are based on current expectations and are subject to uncertainties that cause actual results to differ materially. These uncertainties are detailed in documents filed regularly with the SEC.
ATEC

6
ATEC / Alphatec Holdings, Inc. 10-Q (Quarterly Report)

2018-08-03 sec.gov
atec-10q_20180630.htm UNITED STATES
ATEC

6
Alphatec to Report Second Quarter 2018 Financial Results on August 2, 2018

2018-07-09 globenewswire
CARLSBAD, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“Alphatec” or the “Company”) (Nasdaq:ATEC), a provider of innovative spine surgery solutions with a mission to improve patient lives through the relentless pursuit of superior outcomes, announced today that the Company plans to release its second quarter 2018 financial results on Thursday, August 2, 2018, after the market closes.
ATEC

69
TransEnterix (TRXC) in Focus: Stock Moves 7% Higher

2018-06-27 zacks - 2
TransEnterix, Inc. (TRXC - Free Report) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $3.13 to $4.78 in the past one-month time frame. The company has not seen any estimate revisions over the past month, while the Zacks Consensus Estimate for the current quarter also remained unchanged.
ATEC TRXC DY ICHR

5
Alphatec Holdings Sees Hammer Chart Pattern: Time to Buy?

2018-06-26 zacks - 1
Alphatec Holdings, Inc. (ATEC - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because ATEC recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
ATEC RCKY

5
ATEC / Alphatec Holdings, Inc. / Healthpointcapital Partners Lp - SC 13D AMENDMENT NO. 5 (Activist Investment)

2018-06-25 sec.gov - 1
SC 13D Amendment No. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
ATEC

5
ATEC / Alphatec Holdings, Inc. / Healthpointcapital Partners Lp - SC 13D AMENDMENT NO. 5 (Activist Investment)

2018-06-25 sec.gov - 1
SC 13D Amendment No. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
ATEC

4
ATEC / Alphatec Holdings, Inc. / Stonepine Capital Management, LLC - null (Passive Investment)

2018-06-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. __)* Alphatec Holdings, Inc.
ATEC

7
ATEC / Alphatec Holdings, Inc. / Stonepine Capital Management, LLC - null (Passive Investment)

2018-06-15 sec.gov - 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. __)* Alphatec Holdings, Inc.
ATEC

4
ATEC / Alphatec Holdings, Inc. null

2018-06-14 sec.gov
CORRESP Alphatec Holdings, Inc. 5818 El Camino Real Carlsbad, CA 92008 May 9, 2018 VIA EDGAR
ATEC

4
ATEC / Alphatec Holdings, Inc. 424B3 (Prospectus)

2018-05-23 sec.gov
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-224304 PROSPECTUS <
ATEC

6
ATEC / Alphatec Holdings, Inc. SD

2018-05-22 sec.gov - 2
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
ATEC

4
ATEC / Alphatec Holdings, Inc. S-8

2018-05-21 sec.gov
S-8 As filed with the Securities and Exchange Commission on May 21, 2018 Registration No. 333-
ATEC

Related Articles

REPH: Recro Pharma Analysis and Research Report

23h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 02081G102